204 related articles for article (PubMed ID: 34280522)
1. Prognostic Role of Cardiopulmonary Exercise Testing in Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Treated With Tafamidis.
Dalia T; Acharya P; Chan WC; Sauer AJ; Weidling R; Fritzlen J; Goyal A; Miller D; Knipper E; Porter CB; Shah Z
J Card Fail; 2021 Nov; 27(11):1285-1289. PubMed ID: 34280522
[TBL] [Abstract][Full Text] [Related]
2. Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy.
Badr Eslam R; Öztürk B; Rettl R; Capelle CDJ; Qin H; Binder C; Dachs TM; Camuz Ligios L; Duca F; Dalos D; Schrutka L; Alasti F; Kastner J; Vila G; Bonderman D
Circ Heart Fail; 2022 Jul; 15(7):e008381. PubMed ID: 35766028
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis.
Nicol M; Deney A; Lairez O; Vergaro G; Emdin M; Carecci A; Inamo J; Montfort A; Neviere R; Damy T; Harel S; Royer B; Baudet M; Cohen-Solal A; Arnulf B; Logeart D
Eur J Heart Fail; 2021 Feb; 23(2):231-239. PubMed ID: 33006180
[TBL] [Abstract][Full Text] [Related]
4. Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
Kuyama N; Takashio S; Oguni T; Yamamoto M; Hirakawa K; Ishii M; Hanatani S; Oda S; Matsuzawa Y; Usuku H; Yamamoto E; Hirai T; Ueda M; Tsujita K
J Am Heart Assoc; 2024 May; 13(10):e034518. PubMed ID: 38761073
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.
Takashio S; Morioka M; Ishii M; Morikawa K; Hirakawa K; Hanatani S; Oike F; Usuku H; Kidoh M; Oda S; Yamamoto E; Matsushita K; Ueda M; Tsujita K
ESC Heart Fail; 2023 Aug; 10(4):2319-2329. PubMed ID: 37073415
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis.
Silverii MV; Argirò A; Baldasseroni S; Fumagalli C; Zampieri M; Guerrieri L; Bartolini S; Mazzoni C; Burgisser C; Tomberli A; Di Mario C; Marchionni N; Olivotto I; Perfetto F; Fattirolli F; Cappelli F
Intern Emerg Med; 2023 Mar; 18(2):585-593. PubMed ID: 36396841
[TBL] [Abstract][Full Text] [Related]
10. Changes in Exercise Tolerance over Time in Patients with Transthyretin Amyloidosis Cardiomyopathy Treated with Tafamidis.
Nakaya Y; Ogimoto A; Kitaoka H
Int Heart J; 2023 Jul; 64(4):647-653. PubMed ID: 37460315
[TBL] [Abstract][Full Text] [Related]
11. Serial Changes in Cardiopulmonary Exercise Testing Parameters in Untreated Patients With Transthyretin Cardiac Amyloidosis.
Argirò A; Silverii MV; Burgisser C; Fattirolli F; Baldasseroni S; di Mario C; Zampieri M; Biagioni G; Mazzoni C; Chiti C; Allinovi M; Ungar A; Perfetto F; Cappelli F
Can J Cardiol; 2024 Mar; 40(3):364-369. PubMed ID: 37793568
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
13. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
15. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
16. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sperry BW; Hanna M; Maurer MS; Nativi-Nicolau J; Floden L; Stewart M; Wyrwich KW; Barsdorf AI; Kapadia H; Spertus JA
JAMA Cardiol; 2023 Mar; 8(3):275-280. PubMed ID: 36723935
[TBL] [Abstract][Full Text] [Related]
17. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
18. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
19. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Elliott P; Gundapaneni B; Sultan MB; Ines M; Garcia-Pavia P
Eur J Heart Fail; 2023 Nov; 25(11):2060-2064. PubMed ID: 37434378
[TBL] [Abstract][Full Text] [Related]
20. Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis.
Yunis A; Doros G; Luptak I; Connors LH; Sam F
Am J Cardiol; 2019 Jul; 124(1):122-130. PubMed ID: 31053293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
